DIRS.INFO The most relevant business & tech news

☆ Pfizer moves forward with once-daily version of weight loss pill after setbacks
▼ + stars: | 2024-07-11 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw "encouraging" data in an ongoing early-stage trial. Pfizer is one of several drugmakers racing to win a slice of the market for a highly popular class of weight loss and diabetes drugs called GLP-1 agonists. At the time, the pharmaceutical giant said phase one trial data on the once-daily version would "inform a path forward." Pfizer's danuglipron is a GLP-1 that promotes weight loss in the same way as Novo Nordisk' s injection Wegovy and diabetes treatment Ozempic. But he said Pfizer was looking for potential licensing deals or earlier-stage weight loss drugs.

Persons: Albert Bourla, Pfizer's, Eli Lilly, Bourla, Mikael Dolsten, Dolsten Organizations: Pfizer, Novo Nordisk, U.S

☆ Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
▼ + stars: | 2024-06-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +19 min

But other current employees are dissatisfied with where the strategy shift has left them. In January 2023, Pfizer forecast a steep drop in annual revenue, to between $67 billion and $71 billion. Pfizer's 2023 revenue ultimately came in at $58.5 billion, including $11.22 billion from its Covid vaccine and $1.28 billion from Paxlovid. Faith in executive leadership also plunged among some workers, according to most of the current and former employees who spoke with CNBC. Some current workers said that hasn't appeared to change after the town hall on May 2.

Persons: Albert Bourla, Wall, they're, Bourla, I'm, drugmaker Seagen, Irfan Khan, hasn't, Pfizer, renegotiating, John Thys, Payal Sahni Becher, Becher, Kena, Mike McDermott, Bourla's Organizations: Corbis, Getty, Pfizer, Wall, CNBC, Los Angeles Times, Moderna, Centers for Disease Control, U.S ., GSK, Bristol Myers Squibb, Pfizer wasn't, . Biotech, Companies, Biotech, BioNtech, Reuters, Human, View Press, Global, APEC, Summit, Tech, Google Locations: U.S, Covid, Eagle Rock , California, Durham , North Carolina, Puurs, Belgium, New York City, Peapack , New Jersey, Kena

☆ Millennials and Gen Zers are 'quiet quitting' friendships, and it could backfire
▼ + stars: | 2024-06-20 | by ( Mikhaila Friel | ) www.businessinsider.com time to read: +5 min

Read previewSome millennials and Gen Zers are embracing "quiet quitting" as a means of ending friendships. "While losing enduring connections can lead to feelings of isolation or missing out, quiet quitting may also be a healthy way for millennials and Gen Zers to prune their social lives, allowing new, richer relationships to grow," he added. Quiet quitting can lead to regret, experts sayMark Vahrmeyer, a psychotherapist and cofounder of Brighton and Hove Psychotherapy, told BI that the consequences of quiet quitting depend on the circumstances. Sophie Mort, a clinical psychologist and mental health expert at Headspace, told BI that quiet quitting to avoid conflict will lead to feelings of regret, as unresolved feelings remain permanently unaddressed. AdvertisementMargaret Bankole, a friendship and relationships counselor, told BI that quiet quitting can be harmful for both sides, as it will ruin the opportunity to gain closure.

Persons: —, Zers, Melissa Ann Marie, Marie, 168,7000, gossiped, Daniel Glazer, Blaquier, Mark Vahrmeyer, Sophie Mort, Margaret Bankole Organizations: Service, Business, Brighton, Hove Psychotherapy Locations: millennials, Argentina, Buenos Aires, Hove

☆ Cramer: Pfizer's Covid sales tapered off much quicker than anyone expected
▼ + stars: | 2024-06-14 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Cramer: Pfizer's Covid sales tapered off much quicker than anyone expectedCNBC's Jim Cramer breaks down his take on Pfizer shares.

Persons: Cramer, Pfizer's, Jim Cramer Organizations: Pfizer

☆ Starbucks is teaming up with an Oscar-winning producer to make Hollywood-style movies and series
▼ + stars: | 2024-06-10 | by ( Lucia Moses | ) www.businessinsider.com time to read: +3 min

Read previewAdd Starbucks to the growing list of brands trying to crack Hollywood. The coffee company announced on Monday the creation of Starbucks Studios to create original entertainment. Related storiesIt's working with Sugar23 — the production company headed by Michael Sugar, best known for the Oscar-winning "Spotlight" — to develop projects. Starbucks' forays into original entertainment go back to 2016, when it released "Upstanders," a series of 10 written, video, and podcast stories about people creating positive change. "Starbucks is being very bold with this but really very smart … You can't reach 30 million people on NBC anymore."

Persons: —, Christy Cain, Sugar23, Michael Sugar, Sugar, Trevor Noah's, Max, Ron Howard, Brian Grazer's, Reese Witherspoon's Organizations: Service, Starbucks Studios, Business, InBev, Procter & Gamble, Time Studios, Productions, Amazon's, Tribeca, NBC, Brands, Netflix, Apple Locations: Rwanda

☆ Starbucks is teaming up with an Oscar-winning producer to make movies and series
▼ + stars: | 2024-06-10 | by ( Lucia Moses | ) www.businessinsider.com time to read: +3 min

☆ FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
▼ + stars: | 2024-06-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

But the virus can also cause severe illness in adults 50 and up — or even younger — with underlying chronic conditions such as asthma, diabetes and congestive heart failure. GSK's shot won't reach that new patient population just yet. Safety data in adults ages 50 to 59 was also consistent with data in adults 60 and above, according to GSK. Regulatory agencies in Europe, Japan and other areas are currently reviewing GSK's application to expand Arexvy's approval to high-risk adults ages 50 to 59. GSK's shot is approved in nearly 50 countries, a spokesperson for the company told CNBC.

Persons: Phil Dormitzer, Dormitzer, Luke Miels, Arexvy, GSK's Organizations: Drug Administration, GSK, FDA, Centers for Disease Control, CNBC, CDC, Pfizer, Moderna, U.S Locations: British, Europe, Japan

☆ FTC prepares to sue largest U.S. alcohol distributor, alleging 'secret kickbacks'
▼ + stars: | 2024-06-05 | by ( Rebecca Picciotto | ) www.cnbc.com time to read: +1 min

Lina Khan, chair of the Federal Trade Commission, speaks during the 2024 CNBC CEO Council Summit in Washington, D.C. on June 4, 2024. The Federal Trade Commission is preparing an antitrust lawsuit against the largest U.S. alcohol distributor, Southern Glazer's Wine and Spirits, two sources familiar with the matter told CNBC. But one source said the commission is likely to allege that Southern Glazer's has been providing "secret kickbacks" to large retail customers and violating the 1936 Robinson-Patman Act. Florida-based Southern Glazer's Wine and Spirits distributes alcohol for over 7,000 brands in 44 states. Under the FTC's interpretation, the Robinson-Patman Act is not a wholesale ban on price discrimination and could allow volume discounts.

Persons: Lina Khan, Robinson Organizations: Federal Trade Commission, CNBC, Summit, Southern, Politico, Forbes Locations: Washington ,, Southern, Florida

☆ FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
▼ + stars: | 2024-05-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Food and Drug Administration on Friday approved Moderna's vaccine for respiratory syncytial virus for adults ages 60 and above, the company's second-ever product to enter the U.S. market. The approval of Moderna's shot is based on a late-stage trial on older adults, who are more vulnerable to severe cases of RSV. The company's shot is also the only RSV vaccine to be available in a pre-filled syringe, which is designed to make it easier to administer to patients. An advisory panel to the CDC will vote in June on recommendations for the use and intended population of Moderna's shot. Moderna's full-year 2024 sales guidance of roughly $4 billion includes revenue from its RSV vaccine.

Persons: Moderna's, Stéphane Bancel Organizations: Drug Administration, Moderna, Centers for Disease Control, CDC, GSK, Pfizer Locations: U.S

☆ Pfizer's drug for advanced lung cancer shows promising long-term trial results
▼ + stars: | 2024-05-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

CHICAGO — Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which may help establish it as the new standard treatment for the condition. The drug, called Lorbrena, also cut the risk of the cancer progressing in patients' brains. Only about 5% of all non-small cell lung cancer patients have the mutation, which causes cancer cells to grow and spread abnormally. But Pfizer's drug isn't currently considered the standard – or the most appropriate and widely used – treatment for the condition. Nearly 300 people in the trial either received Lorbrena or Pfizer's older lung cancer drug Xalkori.

Persons: isn't, Chris Boshoff, Lorbrena, David Spigel, Sarah Cannon, Spigel, Andrew Berens, Pfizer's Boshoff Organizations: CHICAGO, Pfizer, CNBC, Lorbrena's, American Society of Clinical Oncology, Clinical Oncology, Sarah, Sarah Cannon Research Institute, Lorbrena, Leerink Locations: U.S, Chicago

☆ Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts
▼ + stars: | 2024-05-22 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The announcement is in addition to another $4 billion cost-cutting effort, which Pfizer announced last year as demand for its Covid vaccine and oral drug Paxlovid slumped. One-time costs related to the initial stage of cuts are expected to be about $1.7 billion, including severance for an unspecified number of laid-off employees. Pfizer also expects the program to involve "product portfolio enhancements" and changes to the company's manufacturing and supply network, a spokesperson told CNBC. "The program will focus on streamlining our ways of working, reducing complexity and increasing productivity in Pfizer Global Supply," the spokesperson said in a statement. Pfizer is trying to shore up investor sentiment after its shares fell nearly 50% in 2023, making it the worst-performing pharmaceutical stock last year.

Persons: Paxlovid, Wall, Albert Bourla Organizations: Pfizer, CNBC, Pfizer Global Supply Locations: New York City

☆ This overlooked obesity-drug stock has 80% upside, JPMorgan says
▼ + stars: | 2024-05-21 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

Structure Therapeutics is an overlooked stock that could surge on the GLP-1 weight loss craze. "Meaningful upside from even a small piece of unprecedentedly large GLP-1 market," JPMorgan said. AdvertisementStructure Therapeutics is developing the drug candidate dubbed "1290," which is a "pure-play option" for the GLP-1 weight loss market, according to JPMorgan. JPMorgan said early results suggest the drug candidate offers "on par" weight loss results for patients with "no major concerns on safety." Advertisement"We think GPCR's market share in the oral market can approach 5% over time in an unprecedentedly large market.

Persons: —, Eli Lilly, Eli, orforglipron, Eli Lilly's Organizations: Therapeutics, JPMorgan, Service, Novo Nordisk, GLPP, Nasdaq

☆ If you're not making progress in therapy, you might be intellectualizing your emotions. Here are 3 signs, according to a therapist.
▼ + stars: | 2024-05-21 | by ( Kim Schewitz | ) www.businessinsider.com time to read: +7 min

You might fixate on understanding why you're feeling this way, why the upsetting situation has occurred, and what you can rationally do to resolve it. AdvertisementShe shared three signs that you might be intellectualizing your feelings and how you can start to feel safe enough to feel them. The goal of therapy should be to support when you're feeling safe enough that you want to feel your feelings." You feel emotionally disconnected from people and things in your lifeFeeling a sense of emptiness or disconnection could be a sign you're intellectualizing your feelings. You're responding normally but you don't feel fully authentic or present because you're thinking too much and you're "stuck in your head."

Persons: —, Trisha Wolfe, Wolfe, they've, They'll, I'm, Intellectualizing Organizations: Service, Business, Systems Locations: Michigan, intellectualizing

☆ Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
▼ + stars: | 2024-05-07 | by ( Scott Olson | Getty Images | ) www.cnbc.com time to read: +10 min

Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield

☆ 3 reasons your teens and 20s are 'the decisive decade'
▼ + stars: | 2024-05-04 | by ( Allie Kelly | ) www.businessinsider.com time to read: +6 min

And there are three key reasons Gen Zers' decisive decade will shape their ongoing mental and financial health. Unhappiness can shape long-term mental healthGen Zer's mental health outcomes are shaped by their involvement in school and work, Brookings researchers said. AdvertisementAt work, many Gen Zers are struggling with anxiety, work-life balance, and burnout — more so than millennials, Gen X, and boomers. Unhappiness and social isolation are especially affecting Gen Zers who reached adolescence during the pandemic. Not all Gen Zers start on equal footingTo be sure, Gen Zers' education, work, and financial outcomes are also dependent on their life circumstances in childhood.

Persons: —, Zers, Gen Zers, Ian Rowe, Gen X, Lara Aknin, it's, Zer, isn't Organizations: Service, Pew, Business, Brookings Institution, Brookings, Urban Institute, American Enterprise Institute, Research Locations: America, Brookings

☆ Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
▼ + stars: | 2024-05-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefiting from its broad cost-cutting program and strong sales of its non-Covid products. Pfizer reiterated its previous revenue forecast of $58.5 billion and $61.5 billion, which it first outlined in mid-December. For the first quarter, Pfizer booked net income of $3.12 billion, or 55 cents per share. That compares with net income of $5.54 billion, or 97 cents per share, during the same period a year ago. Paxlovid booked $2 billion in revenue for the quarter, down 50% from the same period a year ago.

Persons: Pfizer's, Paxlovid Organizations: Pfizer, Wednesday, LSEG, Revenue, U.S, Paxlovid Locations: U.S, Seagen, China

☆ Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly
▼ + stars: | 2024-04-26 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

It's a week jam-packed with notable events, including earnings from Apple , Amazon and Eli Lilly . He also said to pay attention to Wednesday's Federal Reserve meeting and Friday's employment figures from the Department of Labor. "We have to run such a ridiculous gauntlet next week that I have no idea how it'll play out," he said. Wednesday also brings reports from Wingstop , Carvana and Marriott . Apple will report on Thursday, and Cramer noted there's been a lot of negative sentiment from investors surrounding the company.

Persons: CNBC's Jim Cramer, Eli Lilly, Jensen Huang, Cramer, it's, he'll, Seagen, there's Organizations: Apple, Federal Reserve, Department of Labor, Nvidia, Food and Drug Administration, Starbucks, CVS, Pfizer, Amazon, Walgreens, Marriott, Vision Locations: It's, China, Wingstop, Carvana

☆ FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
▼ + stars: | 2024-04-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The Food and Drug Administration on Friday approved Pfizer 's treatment for a rare genetic bleeding disorder, making it the company's first-ever gene therapy to win clearance in the U.S. The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements. Without that protein, called factor IX, patients with hemophilia B bruise easily and bleed more frequently and for longer periods of time. The gene therapy will compete with Australia-based CSL Behring's Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. The company is also developing a gene therapy for Duchenne muscular dystrophy, a genetic disorder that causes muscles to weaken gradually.

Persons: IX, hemophilia, Adam Cuker, Cuker Organizations: Drug Administration, Pfizer, U.S, Penn's, Spark Therapeutics, hemophilia Locations: U.S, Australia

☆ 'Civil War' Director Alex Garland Says His Movie Is Political, Despite Criticism
▼ + stars: | 2024-04-16 | by ( Caralynn Matassa | ) www.businessinsider.com time to read: +13 min

But the writer-director's latest film, "Civil War," isn't about to spoon-feed its message to audiences, either. He wants "Civil War" to make the viewer think, question, and, most importantly, feel. There's been plenty of conversation around how to interpret the message of "Civil War," but you've also been a bit misinterpreted lately. For example, one of the journalists in "Civil War" says, "Oh no, it's like the race to Berlin." She's having an internal state of civil war, which then goes into its own state of collapse.

Persons: Alex Garland doesn't, Garland, Lee, Kirsten Dunst, Joel, Wagner Moura, It's, they'd, There's, you've, freaked, Jonathan Glazer's, it's, straightforwardly, They're imaginatively, We've, hasn't, He's, There'd, they're, Cailee, Kirsten Dunst's Lee, I'm, — Organizations: White, DC Locations: Washington, DC, California, Texas, Berlin, Lee

☆ Comeback candidates: Goldman loves these underperforming stocks with strong fundamentals
▼ + stars: | 2024-04-10 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Stocks that have missed out on this year's market rally could be solid contenders for a rebound, according to Goldman Sachs. Heading into the second quarter, Goldman searched for buy-rated names in its coverage universe that could win big going forward. Goldman screened for "compounders," which offer investors high financial returns, free cash flow generation, margin expansion and sales growth. Most analysts covering the stock currently have a buy rating assigned to the name, with about 39% upside to the consensus price target, per LSEG. Pfizer stock has slipped 9% this year.

Persons: Goldman Sachs, Goldman, Dan Levy, Levy, Guggenheim, Vamil Divan, Lamb Weston, Jefferies, Rob Dickerson Organizations: Barclays, Pfizer Locations: U.S

☆ Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
▼ + stars: | 2024-04-09 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday. The initial data suggests that Pfizer's shot, known as Abrysvo, could help protect a far wider population from RSV. The jab is currently approved in the U.S., Europe, Japan and other countries for adults ages 60 and older and expectant mothers who can pass on protection to their fetuses. Nearly 10% of U.S. adults ages 18 to 49 have a chronic condition that puts them at risk of severe RSV disease, according to Pfizer. GSK's RSV vaccine for adults ages 60 and above booked around £1.2 billion ($1.5 billion) in sales last year.

Persons: Dr, Iona Munjal, Pfizer's Organizations: Pfizer, CNBC, GlaxoSmithKline Locations: U.S, Europe, Japan

☆ Cramer's Lightning Round: Leidos is a winner
▼ + stars: | 2024-03-28 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Core & Main's year-to-date stock performance. Stock Chart Icon Stock chart icon Pfizer's year-to-date stock performance. Stock Chart Icon Stock chart icon SFL's year-to-date stock performance. Stock Chart Icon Stock chart icon Leidos' year-to-date stock performance. Stock Chart Icon Stock chart icon KLA's year-to-date stock performance.

Persons: it's, They've, Leidos, that's, Mike Wirth's, I'm, It's Organizations: Pfizer, Chevron

Shop at Amazon Shop at DreoTyphur Sous Vide Station If you’ve been wanting to venture into the benefits of cooking with Sous Vide, Typhur’s Sous Vide Station incorporates all functions of sous vide cooking into one unit, with a built-in tank, scheduling functions, and step-by-step cooking instructions on a large LCD display. Shop at Amazon Shop at TramontinaAdvertisementSustainability and alternative materialsEco-friendly materials are at the forefront of home and kitchen design. Shop at Amazon Shop at UmbraFull Circle Grate Expectations Stainless Steel Coarse Grater with Food Catcher Full Circle should be on your radar for eco-friendly cleaning tools and hydration solutions. From earth tones and pastels to vibrant collections, you can coordinate your kitchen in monochrome hues, prints, and textures. Shop at Amazon Shop at Walmart Shop at TargetLuma Nugget Countertop Ice Maker We've been searching for a more affordable nugget ice maker, and this small appliance from Luma might be the one.

Persons: It's, Dreo ChefMaker Combi Fryer, you’ve, Zyliss, Joe Derochowski, Dyson, Brabantia Organizations: Business, Shop, kraft, Cork, Walmart, Everest

☆ It's no wonder why 'Zone of Interest' earned 2 Oscars. It showed us the Holocaust like never before.
▼ + stars: | 2024-03-11 | by ( Mathias Döpfner | ) www.businessinsider.com time to read: +10 min

The images and sounds from A24's "Zone of Interest," which has earned a little over $24 million at the global box office, have haunted me since that weekend. AdvertisementUnlike most Holocaust films, Jonathan Glazer, the director of "The Zone of Interest," tells the story from the perpetrators' — and thus the murderers' — perspective. More precisely, he tells the story of Rudolf Höss, the camp commander of Auschwitz, one of the worst criminals of National Socialism. 'Zone of Interest' perfectly captures a life with no loveA still from "The Zone of Interest." Shortly after the meeting, the Höss family once again goes swimming in the river.

Persons: Axel Springer, Mathias Döpfner, Jonathan Glazer, —, Palme, Martin Amis, Rudolf Höss, Hedwig Höss, Rudolf, it's Rudolf Höss, Christian Friedel, Sandra Hüller, loveless, Hedwig, It's, Kurt Prüfer, Fritz Sander, Höss, Nora Mattaliano, Glazer, Queen, Mica Levi, resound, Höss strolls, Hannah Arendt, Eichmann Organizations: Service, Höss, Wannsee Conference, Holocaust, Museum Locations: WELT, Cannes, Auschwitz, Erfurt, Euphemistic, Berlin, Polish, Washington

☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
▼ + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +13 min

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.

Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California

Search resuls for: "Zer's"

25 mentions found